STXS

STEREOTAXIS INC

Healthcare | Micro Cap

-$0.04

EPS Forecast

$10.38

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Stereotaxis Q3 2026: Two Transformations in Progress as Revenue Rises but Cash Burns

Ticker: STXS. In this update, the company walks the line between a promising pivot to a scalable platform and the operational reality of cash burn. EPS and EPS consensus are not disclosed in the release, leaving investors to read the tea leaves of revenue, margins, and liquidity indicators.

Overview: Revenue grows, but liquidity remains a watchful eye

Stereotaxis (NYSE: STXS) reported third-quarter 2026 revenue of $8.9 million, up 20% from the prior-year third quarter and up 16% sequentially from the second quarter. Within that, system revenue was $3.0 million, improving from $1.9 million a year earlier, while recurring revenue totaled $5.9 million, rising 6% year over year but slipping 4% quarter over quarter.

The company highlights a mixed-margin profile: overall gross margin was 45% of revenue, with recurring revenue margins at 59% and system margins at 15%. The rigid, fixed overhead squeeze at low production volumes keeps margins under pressure, a common feature for a growth-stage medtech platform making a transition from capital equipment sales to a more recurring-revenue mix.

On the cost side, reported operating expenses for the quarter were $10.4 million, including $1.3 million of non-cash charges related to stock compensation, acquisition-related items, and amortization of acquired intangibles. Excluding those charges, adjusted operating expenses were $9.1 million, up from $6.6 million a year ago due to one-time acquisition costs and the absorption of Robocath-related expenses.

Results: Losses persist, but the shapes of the losses are changing

Operating loss and net loss for the quarter were both $(6.5) million, a result that sits alongside a previously improved baseline but remains in the red versus the prior year. On an adjusted basis, operating loss was $(5.1) million and adjusted net loss was $(5.2) million, reflecting the dilution from one-time transaction costs and the clouding impact of absorbing Robocath operating expense.

Cash burn showed no mercy: negative cash flow of $(6.5) million for the quarter, with about $(2.6) million tied to the core Stereotaxis business and $(3.9) million connected to Robocath-related payments. At quarter-end, cash and cash equivalents stood at $4.0 million.

Liquidity considerations and strategic financing

Concurrent with these results, Stereotaxis announced a convertible note financing of up to $24 million, with an initial upfront close described in the filing. This liquidity runway underpins the company’s longer-term pivot and may influence how investors price the equity story over the next few quarters.

Two large-scale transformations in motion

The company reiterates its near-term strategic pivot toward two big ideas:

  • Accessibility and scalability of systems: moving away from long, capital-intensive sales and construction timelines toward a portfolio of systems designed for easier deployment and broader addressable demand.
  • Disposable catheter portfolio and recurring revenue: developing and commercializing a line of robotically navigated catheters to unlock a substantial recurring revenue stream and bolster robot value in procedures.

The third quarter saw meaningful progress: GenesisX system shipments in the United States and China, plus a substantive rollout of Synchrony digital operating room systems in the US, contributing to the revenue mix. The company also closed the Robocath acquisition and disclosed a Canon collaboration, signaling a broader platform strategy rather than a single product thesis.

Backlog for disposable orders was approximately $1.9 million at the start of the fourth quarter, held back in part by supply constraints. This nuance matters: even with a growing installed base and installed-catheter ecosystem, the pace of revenue realization can lag the pace of demand if components are scarce.

Outlook and what it portends for STXS and peers

Given the absence of a formal quarterly revenue forecast in the press materials, investors are left to infer trajectory from the mix shift (recurring versus system), the pipeline (robotic catheters, digital OR capabilities), and the funding runway. In the context of company earnings dynamics, the lack of an EPS figure and absence of a stated EPS consensus create a natural area of ambiguity—any potential earnings surprise will hinge on how quickly the disposable catheter portfolio scales and how efficiently Robocath is integrated.

From a strategic vantage, the dual emphasis on a scalable hardware platform and a robust catheter ecosystem could position STXS to weather volume volatility in endovascular procedures better than a pure capital-equipment model. The Canon collaboration adds a data-and-automation layer that can improve ROIC over time, provided operational integration meets expectations. For sector peers, the move toward a more recurring revenue orientation—if it can sustain margin progression—may become a calibration point for medtech robotics players grappling with episodic procedure volumes and supply chain fragility.

Takeaways for investors and peers

  • The STXS story hinges on transformation momentum as much as quarterly results. The shift toward disposable catheters and a platform strategy could unlock longer-term revenue visibility beyond quarterly noise.
  • Liquidity remains a critical watch item. A $4 million cash balance paired with a $24 million convertible facility suggests a narrowly framed liquidity runway that could accelerate or constrict depending on working capital needs and M&A integration costs.
  • Backlog and supply constraints underscore a classic medtech risk: demand exists, but the supply chain or manufacturing capacity can bottleneck near-term execution.
  • The acquisitions (Robocath) and partnerships (Canon) signal a broader strategy to turn robotics into a platform—if successful, this could tilt competitive dynamics in the sector toward multi-product ecosystems with recurring revenue components.

Note: This summary uses metrics such as revenue, gross margin, and cash flow to outline the quarter, and comments on EPS and EPS consensus reflect typical investor frameworks. The absence of explicit EPS data in the filing means any EPS consensus or earnings surprise assessment would require forthcoming reporting data.